Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker OGN · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Aug 17, 2026 | NEXPLANON ETONOGESTREL | OGN Organon | New drug (NDA), supplement REMS | NDA021529 ↗ |
| Jul 6, 2026 | ELOCON MOMETASONE FUROATE | OGN Organon | New drug (NDA), supplement Labeling | NDA019796 ↗ Letter or label ↗ |
| Jul 6, 2026 | ELOCON MOMETASONE FUROATE | OGN Organon | New drug (NDA), supplement Labeling | NDA019625 ↗ Letter or label ↗ |
| Jul 6, 2026 | ELOCON MOMETASONE FUROATE | OGN Organon | New drug (NDA), supplement Labeling | NDA019543 ↗ Letter or label ↗ |
| May 28, 2026 | NEXPLANON ETONOGESTREL | OGN Organon | New drug (NDA), supplement Labeling | NDA021529 ↗ |
| May 15, 2026 | Jada System (Jada-2002) | OGN Organon, LLC | Device clearance (510(k)) Traditional | K253642 ↗ |
| Mar 19, 2026 | SINEMET CR CARBIDOPA; LEVODOPA | OGN Organon LLC | New drug (NDA), supplement Labeling | NDA019856 ↗ |
| Mar 19, 2026 | SINEMET CARBIDOPA; LEVODOPA | OGN Organon | New drug (NDA), supplement Labeling | NDA017555 ↗ |
| Mar 18, 2026 | PROSCAR FINASTERIDE | OGN Organon | New drug (NDA), supplement Labeling | NDA020180 ↗ |
| Feb 3, 2026 | FOSAMAX PLUS D ALENDRONATE SODIUM; CHOLECALCIFEROL | OGN Organon LLC | New drug (NDA), supplement Labeling | NDA021762 ↗ |
| Feb 3, 2026 | FOSAMAX ALENDRONATE SODIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA020560 ↗ |
| Jan 16, 2026 | NEXPLANON ETONOGESTREL | OGN Organon | New drug (NDA), supplement Efficacy | NDA021529 ↗ |
| Jul 23, 2025 | REMERON MIRTAZAPINE | OGN Organon | New drug (NDA), supplement Manufacturing (CMC) | NDA020415 ↗ |
| Jun 20, 2025 | HYZAAR HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA020387 ↗ |
| Jun 20, 2025 | COZAAR LOSARTAN POTASSIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA020386 ↗ |
| Jun 5, 2025 | DULERA FORMOTEROL FUMARATE; MOMETASONE FUROATE | OGN Organon LLC | New drug (NDA), supplement Manufacturing (CMC) | NDA022518 ↗ |
| Dec 12, 2024 | VTAMA TAPINAROF | OGN Organon LLC | New drug (NDA), supplement Efficacy | NDA215272 ↗ |
| Oct 28, 2024 | LIPTRUZET ATORVASTATIN CALCIUM; EZETIMIBE | OGN Organon | New drug (NDA), supplement Labeling | NDA200153 ↗ Letter or label ↗ |
| Oct 28, 2024 | LIPTRUZET ATORVASTATIN CALCIUM; EZETIMIBE | OGN Organon | New drug (NDA), supplement Labeling | NDA200153 ↗ Letter or label ↗ |
| Oct 28, 2024 | LIPTRUZET ATORVASTATIN CALCIUM; EZETIMIBE | OGN Organon | New drug (NDA), supplement Labeling | NDA200153 ↗ Letter or label ↗ |
| Jul 8, 2024 | CELESTONE SOLUSPAN BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE | OGN Organon | New drug (NDA), supplement Labeling | NDA014602 ↗ |
| Jun 5, 2024 | CELESTONE SOLUSPAN BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE | OGN Organon | New drug (NDA), supplement Labeling | NDA014602 ↗ |
| Mar 28, 2024 | VYTORIN EZETIMIBE; SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA021687 ↗ |
| Feb 21, 2024 | ZETIA EZETIMIBE | OGN Organon | New drug (NDA), supplement Labeling | NDA021445 ↗ |
| Feb 8, 2024 | VYTORIN EZETIMIBE; SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA021687 ↗ Letter or label ↗ |
| Feb 8, 2024 | VYTORIN EZETIMIBE; SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA021687 ↗ Letter or label ↗ |
| Feb 8, 2024 | VYTORIN EZETIMIBE; SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA021687 ↗ Letter or label ↗ |
| Sep 29, 2023 | NEXPLANON ETONOGESTREL | OGN Organon | New drug (NDA), supplement Labeling | NDA021529 ↗ |
| Sep 29, 2023 | NEXPLANON ETONOGESTREL | OGN Organon | New drug (NDA), supplement Labeling | NDA021529 ↗ |
| Sep 29, 2023 | NEXPLANON ETONOGESTREL | OGN Organon | New drug (NDA), supplement Labeling | NDA021529 ↗ |
| Aug 9, 2023 | ZOCOR SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA019766 ↗ |
| Jul 20, 2023 | ZETIA EZETIMIBE | OGN Organon | New drug (NDA), supplement Labeling | NDA021445 ↗ |
| Mar 17, 2023 | HYZAAR HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA020387 ↗ |
| Mar 14, 2023 | ZOCOR SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA019766 ↗ |
| Mar 6, 2023 | XACIATO CLINDAMYCIN PHOSPHATE | OGN Organon LLC | New drug (NDA), supplement Labeling | NDA215650 ↗ |
| Sep 6, 2022 | CELESTONE SOLUSPAN BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE | OGN Organon | New drug (NDA), supplement Labeling | NDA014602 ↗ |
| Aug 1, 2022 | PROPECIA FINASTERIDE | OGN Organon | New drug (NDA), supplement Labeling | NDA020788 ↗ |
| Jun 28, 2022 | NASONEX MOMETASONE FUROATE | OGN Organon LLC | New drug (NDA), supplement Labeling | NDA020762 ↗ |
| May 31, 2022 | ZOCOR SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA019766 ↗ |
| May 23, 2022 | VTAMA TAPINAROF | OGN Organon LLC | New drug (NDA) Type 1 - New Molecular Entity | NDA215272 ↗ Letter or label ↗ |
| Mar 7, 2022 | ZOCOR SIMVASTATIN | OGN Organon | New drug (NDA), supplement Labeling | NDA019766 ↗ |
| Dec 7, 2021 | XACIATO CLINDAMYCIN PHOSPHATE | OGN Organon LLC | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA215650 ↗ |
| Nov 18, 2021 | REMERON MIRTAZAPINE | OGN Organon | New drug (NDA), supplement Labeling | NDA020415 ↗ Letter or label ↗ |
| Oct 15, 2021 | COZAAR LOSARTAN POTASSIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA020386 ↗ Letter or label ↗ |
| Aug 25, 2021 | PROSCAR FINASTERIDE | OGN Organon | New drug (NDA), supplement Labeling | NDA020180 ↗ |
| Jun 15, 2021 | PROPECIA FINASTERIDE | OGN Organon | New drug (NDA), supplement Labeling | NDA020788 ↗ Letter or label ↗ |
| Jun 15, 2021 | PROSCAR FINASTERIDE | OGN Organon | New drug (NDA), supplement Labeling | NDA020180 ↗ Letter or label ↗ |
| Apr 13, 2021 | PROSCAR FINASTERIDE | OGN Organon | New drug (NDA), supplement Labeling | NDA020180 ↗ Letter or label ↗ |
| Feb 22, 2021 | SINGULAIR MONTELUKAST SODIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA021409 ↗ Letter or label ↗ |
| Feb 22, 2021 | SINGULAIR MONTELUKAST SODIUM | OGN Organon | New drug (NDA), supplement Labeling | NDA020830 ↗ Letter or label ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:05 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates